



# Introduction: Evaluation of the use of a three-antigen HepB vaccine candidate (PREHEVBRIO) for adult vaccination

**Kevin Ault, MD**

Hepatitis Vaccines Work Group, Advisory Committee on Immunization Practices  
January 12, 2022

# Overview: ACIP Hepatitis Work Group

- 1. 40<sup>th</sup> anniversary of HepB vaccine recommendations in the United States**
- 2. Universal adult vaccination recommendation – Nov 3, 2021**
- 3. FDA Approval of PreHevbrio, a three-antigen HepB vaccine – Nov 30, 2021**

Proper Name: Hepatitis B Vaccine (Recombinant)

Tradename: PREHEVBRIO

Manufacturer: VBI Vaccines, Inc.

Indication: For prevention of infection caused by all known subtypes of the hepatitis B virus in adults 18 years and older.

<https://www.fda.gov/vaccines-blood-biologics/prehevbrio>

# ACIP Hepatitis Work Group Members

## ACIP Voting Members

Kevin Ault (Chair)  
Sybil Cineas

## Liaison Representatives

Elizabeth Barnett (AAP)  
Marci Drees (SHEA)  
Sharon McMullen (ACHA)  
Brenna Hughes (ACOG)  
Susan Lett (CSTE)  
Pamela Rockwell (AAFP)  
Matthew Zahn (NACCHO)

## Ex Officio Members

Marian Major (FDA)  
Darcie Everett (FDA)  
Rajen Koshy (NIAID/NIH)  
Chinedu Okeke (HHS)  
Jessica Deerin (HHS)

## Consultants

Sharon Frey (SLU)  
Robert Frenck (CCHMC)  
Prabhu Gounder (LA-DPH)  
Kathleen Harriman (CDPH)  
Brian McMahon (ANTHC)  
Kelly Moore (IAC)  
David Nace (AMDA)  
Jennifer Rosen (NYC-DOH)  
Ann Thomas (OR-DHS/OHA)  
Jennifer Zipprich (MDPH)

## CDC Lead

Mark Weng  
(CDC/Division of Viral Hepatitis)

## CDC Subject Matter Experts

Erin Connors  
Mona Doshani  
Penina Haber  
Megan Hofmeister  
Mohammed Khan  
Neil Murthy  
Lakshmi Panagiotakopoulos  
Noele Nelson  
Priti Patel  
Tom Shimabukuro  
Phil Spradling  
Carolyn Wester